Selective Inhibition of Phosphodiesterase 7 (PDE7) by BRL50481 in Healthy and Ovalbumin-Sensitized Guinea Pigs
Phosphodiesterase (PDE) inhibitors may have significant clinical benefit in respiratory diseases associated with inflammation. The aim was to evaluate effects of selective PDE7 inhibitor (BRL50481) on citric acid induced cough, in vivo and in vitro airway smooth muscle reactivity in both healthy and ovalbumin sensitized guinea pigs, as well as its effectiveness in changes of blood cells count.
Tested drugs were administered intraperitoneally to male guinea pigs once daily for 7 days either vehicle 10% DMSO (dimethyl sulfoxide) 3 ml/kg (as control) or BRL50481 1 mg/kg. Double chamber whole body plethysmograph was used for evaluation of citric acid (0.6 M) induced cough and specific airway resistance. Organ bath method was used for measurement of tracheal and lung tissue strips contractions evoked by cumulative doses (10-8 - 10-3 mol/L) of acetylcholine (ACH) and histamine (HIS).
In healthy guinea pigs we did not observe significant effect of tested drug BRL50481 on in vitro contractions (similarly to in vivo conditions). The effect on cough was in healthy animals negligible. In ovalbumin-sensitized animals, more pronounced in vitro relaxing effect of BRL50481 in HIS induced contractions was observed with similar results in vivo and no significant change in number of cough efforts.
Our results suggest that PDE7 inhibitors have stronger anti-inflammatory effect compared to its direct effect on smooth muscle and cough.
Ichimura M. Kase H. A new cyclic nucleotide phosphodiesterase isoenzyme expressed in the T-lyphocyte cell lines. Biochem Biophys Res Commun 1993; 193: 985-90.
Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kokkawa H, Omori K, Kaminuma O. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 2002; 128: 460-6.
Jones NA, Leport M, Holand T, Vos T, MOrgan M, Fink M, Pruniaux MP, Berthelier C, O'Connor BJ, Bertrand C, Page CP. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. Pulm Pharmacol Therap 2007; 20: 60-8.
Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Nagahira A, Hayashi Y, Kagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y, Nishimura T. ASB16165, a novel inhibitor for phos-phodiesterase 7A (PDE7A), supresses IL-12-induced IFN- production by mouse activated T lymphocytes. Immunol Letters 2009; 122: 193-7.
Mokry J, Nosalova G, Mokra D. Influence of xanthine derivatives on cough and airway reactivity in guinea pigs. J Physiol Pharmacol 2009; 60 (Suppl 5): 87-91.
Mokra D, Mokry J. Meconium aspiration syndrome. From pathomechanisms to treatment. 1st ed. Nova Science Publishers: New York, 2010, 130 p.
Nosalova G, Mokry J. The mechanism of action of xanthine derivatives and suppression of cough. Acta Med Mart 2001; 1: 14-8.
Usmani OS, Belvisi MG, Patel HJ, et al. Theobromine inhibits sensory nerve activation and cough. FASEB J 2004: 2-16.
Antoniu SA. Roflumilast for the treatment of chronic obstructive pulmonary disease. Curr Opin Investig Drugs 2006; 7: 412-7.
Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167-75.
Spina D, Landells LJ, Page CP. The role of theophylline and phosphodiesterase4 isoenzyme inhibitors as anti-inflammatory drugs. Clin Exp Allergy 1998; 28 (Suppl 3): 24-34.
Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011; 32(8): 495-505.
Chung KF. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 2006; 533: 110-7.
Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008; 155: 308-15.
Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520.
Karish SB, Gagnon JM. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor. Ann Pharmacother 2006; 40: 1096-104.
Fabbri LM, Beghe B, Yasothan U, Kirkpatrick P. Roflumilast. Nature Reviews Drug Discovery 2010; 9: 761-762.
Giembycz MA, Field SK. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 2010; 4: 147-158.
Mokry J, Mokra D, Nosalova G, Beharkova M, Feherova Z. Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol 2008; 59 (suppl. 6): 473-82.
Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA. Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes. Molecular Pharmacology 2004; 66(6): 1679-1689.
Morales-Garcia JA, Redondo M, Alonso-Gil S, Gil C, Perez C, Martinez A, Santos A, Perez-Castillo A. Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson Disease. PLoS ONE 2011; 6(2): e17240.
Franova S, Nosalova G, Pechanova O, Sutovska M. Red wine polyphenolic compounds inhibit tracheal smooth muscle contraction during allergen-induced hyperreactivity of the airways. J Pharm Pharmacol 2007; 59: 727-32.
Sutovska M, Franova S, Sutovsky J. The influence of animal species on the relationship between ATP-sensitive potassium ion channels and defense reflexes of the airways. Bratisl Med J 2009; 110 (5), 269-275.
Strapkova A, Nosalova G, Banovcin P, Giacova D. Changes in airway smooth muscle reactivity after exposure to toluene. Stud Pneumol Phthiseol 1995; 55: 263-71.
Javorka K, Calkovska A, Mokra D, Tonhajzerova I. Medical Physiology. Laboratory Manual. Comenius University, Bratislava, 2006, p. 143.
Beeh KM, Beier J, Lerch C, Schulz AK, Buhl R. Effects of Piclamilast, a Selective Phosphodiesterase-4 Inhibitor, on Oxidative Burst of Sputum Cells From Mild Asthmatics and Stable COPD Patients. Lung 2004; 182: 369-77.
Giembycz MA. Phosphodiesterase-4: Selective and Dual-Specificity Inhibitors for the Therapy of Chronic Obstructive Pulmonary Disease. Proc American Thor Soc 2005b; 2: 326-33.
Rabe KF, Bateman ED, O'Donnel D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-71.
Ghosh R, Sawant O, Ganpathy P, Pitre S, Kadam VJ. Phosphodiesterase inhibitors: their role and implications. Int J PharmTech Res 2009; 1(4): 1148-60.
Paterniti I, Mazzon E, Gil C, Impellizzeri D, Palomo V, Redondo M, Perez DI, Esposito E, Martinez A, Cuzzocrea S. PDE7 inhibitors: new potential drugs for the therapy of spinal cord injury. PLoS ONE 2011; 6(1): e15937.
Guo J, Watson A, Kempson J, Carlsen M, Barbosa J, Stebbins K, Lee D, Dodd J, Nadler SG, McKinnon M, Barrish J, Pitts WJ. Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorganic Medicinal Chmistry Letters 2009; 19: 1935-8.
Pitts WJ, Vaccaro W, Huynh T, Leftheris K, Roberge JY, Barbosa J, Guo J, Brown B, Watson A, Donaldson K, Starling GC, Kiener PA, Poss MA, Dodd JH, Barrish JC. Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorganic Medicinal Chemistry Letters 2004; 14: 2955-8.
Fortin M, D'Anjou H, Higgins ME, Gougeon J, Aube P, Moktefi K, Mouissi S, Seguin S, Seguin R, Renzi PM, Paquet L, Ferrari N. A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice. Respiratory Res 2009; 10:39.
Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005a; 5: 238-44.